Cisplatin for injection 100 mg/m2

Phase 2

Cisplatin for injection 100 mg/m2 is one of 35 therapeutic programs targeting Oral Mucositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Oral MucositisActive, not recruiting

Oral MucositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Duragesic

CCephalon

Phase 3

2 5

Bactroban

PPadagis LLC

Phase 3

1 6

Neurontin

VViatris Specialty LLC

Phase 3

1 7

Benadryl

PParkedale

Phase 3

1 8

Curcumin

Merck & Co.

Phase 3

2 9

N-Acetyl Cyteien

SStanford University

Phase 3

2 10

Zinc Acetate

NNobelpharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Oral Mucositis

NCT05966194

Clinical

Trials by Indication[1]

Oral Mucositis1 trial

A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT05966194·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cisplatin for injection 100 mg/m2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cisplatin for injection 100 mg/m2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — EpicentRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: EEpicentRx, Inc.

Cisplatin for injection 100 mg/m2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Oral Mucositis1 trial

References

Drug Info

Quick Facts

Related News